INTRODUCTION
============

Homologous recombination (HR) is a major pathway for the elimination of DNA double-strand breaks (DSBs) induced by genotoxic agents or that arise from endogenous damage and replication fork demise. As such, HR is critical for maintaining genome integrity and important for cancer avoidance in humans ([@B1; @B2; @B3]). Paradoxically, intermediates generated by the HR machinery can trigger prolonged arrest of the cell cycle ([@B4]), and the aberrant resolution of these intermediates can lead to gross chromosomal rearrangements, such as translocations ([@B5],[@B6]). Moreover, the HR machinery can interfere with other DNA repair pathways, such as *RAD6/RAD18*-mediated post-replicative repair (PRR) ([@B4],[@B7]). For these reasons, cells possess multiple mechanisms to prevent untimely and deleterious HR events. One such mechanism is mediated by the *SRS2* (Suppressor of RAD Six screen mutant 2) gene in *Saccharomyces cerevisiae*.

A mutant variant of *SRS2* was first recognized as a suppressor of the DNA damage sensitivity of *rad6*or *rad18*mutants ([@B8]). Suppression of the *rad6* or *rad18* DNA repair defect by the *srs2* mutation requires that HR be functional ([@B9]), suggesting that *SRS2* negatively regulates HR. By attenuating HR, it is thought that *SRS2* helps ensure the channeling of DNA lesions encountered by the DNA replication machinery into the Rad6/Rad18-mediated PRR pathway. Yeast strains harboring certain *SRS2* mutations also exhibit a hyper-recombination phenotype, failure to recover from DNA damage checkpoint-mediated G2/M arrest, and synthetic lethality with a variety of other mutations, such as *sgs1,* that affect DNA metabolism ([@B10]). The synthetic lethality of these double mutants often can be overcome by eliminating HR ([@B11],[@B12]), implicating inappropriate HR events as the cause of lethality.

As a member of the SF1 family of nucleic acid unwinding enzymes ([@B13]), Srs2 possesses ssDNA-dependent ATPase and DNA helicase activities ([@B14],[@B15]). In concordance with the genetic data, Srs2 strongly inhibits the formation of DNA joints in *in vitro* recombination reactions that are mediated by the Rad51 recombinase ([@B16],[@B17]). Extensive biochemical and electron microscopic analyses have shown that Srs2 accomplishes this feat by disrupting the Rad51 presynaptic filament, comprised of a right-handed Rad51 helical polymer assembled on ssDNA ([@B16],[@B17]), that catalyzes recombination reactions ([@B18]). The Rad51 presynaptic filament dissociative function and HR attenuating role of Srs2 require its ATPase activity ([@B19]). Srs2 interacts with the sumoylated form of the proliferating cell nuclear antigen (PCNA) at DNA replication forks ([@B20],[@B21]). This serves to target Srs2 to DNA replication forks to prevent Rad51 presynaptic filament assembly, thereby avoiding unwanted recombination during DNA replication ([@B20],[@B21]). Interestingly, when PCNA is not able to be sumoylated, Srs2 recruitment to S phase replication fork foci is decreased, while its recruitment to recombination foci is unaffected ([@B22]). This reveals that recruitment of Srs2 to replication forks or sites of recombination are independent processes.

Interestingly, even though Srs2 suppresses spontaneous recombination events, it facilitates DSB repair by the synthesis-dependent single-strand annealing (SDSA) pathway of HR ([@B23; @B24; @B25]). In addition to its DSB repair function, Srs2 has been shown to have a role in DNA damage checkpoint activation during S phase ([@B26]) and to act with DNA polymerase δ to suppress DNA triplet repeat expansion, possibly by unwinding DNA stem-loop structures formed by the repeats ([@B27],[@B28]).

By yeast two hybrid and biochemical analyses, Srs2 was found to physically interact with Rad51 ([@B16]). However, the significance of the Rad51-Srs2 complex with regards to the anti-recombinase function of Srs2 is not clear. Here, we finely map the Rad51 interaction domain in Srs2 and generate mutant srs2 forms that retain ATP hydrolysis and helicase activities, but differ in their ability to interact with Rad51. We show that the Rad51 interaction-deficient mutant srs2 proteins are attenuated for the Rad51 presynaptic filament dissociative function. Our results thus reveal a requirement for complex formation with Rad51 in the anti-recombinase function of Srs2.

MATERIALS AND METHODS
=====================

Yeast two-hybrid assay
----------------------

*RAD51*was fused to the *GAL4* transcription activation domain in the vector pGAD10, and a C-terminal *SRS2* fragment encompassing residues 783--1174 harboring the Rad51 interaction domain ([@B16]) was fused to the *GAL4* DNA-binding domain in pGBKT7. The pGAD10-*RAD51* and pGBKT7-srs2 plasmids were introduced into haploid yeast strains PJ69-4a (*MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4Δ gal80Δ LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ*) and PJ69-4α (*MATα trp1-901 leu2-3,112 ura3-52 his3-200 gal4Δ gal80Δ LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ*), respectively ([@B29],[@B30]). Diploid strains obtained by mating plasmid-bearing PJ69-4a and PJ69-4α haploids were grown on synthetic medium lacking tryptophan and leucine ([@B30]). To select for two-hybrid interactions, which would result in the activation of the *ADE2* or *HIS3* reporter genes, diploid cells were replica-plated on synthetic medium lacking tryptophan, leucine and adenine, or on synthetic medium lacking tryptophan, leucine and histidine, respectively. Both plating gave the same results. Only the plating on the tryptophan, leucine and adenine dropout medium is shown in [Figure 1](#F1){ref-type="fig"}A. Additional pGBKT7-based plasmids containing Srs2 residues 783--998, 783--914 and 783--862 were also tested for interaction with Rad51. Figure 1.Two-hybrid interactions of Rad51 with Srs2. (**A**) Fragments of Srs2 were tested for two-hybrid interaction with Rad51 by plating on medium lacking leucine, tryptophan and adenine. The empty vector (pGBKT7) and plasmid harboring *RAD52* were included as negative and positive controls, respectively. (**B**) A schematic of the helicase and protein-protein interaction domains in Srs2. (**C**) Purified Srs2, srs2 1--998, srs2 1--910, srs2 1--860, srs2 1--890 and srs2 1--875, 1 µg each, were analyzed by SDS-PAGE and stained with Coomassie Blue.

Plasmid construction
--------------------

The pET11c-(His)~9~-*SRS2* plasmid was generated by site-directed mutagenesis (Stratagene) of pET11c-*SRS2*, resulting in the addition of an N-terminal 9-histidine tag to the open reading frame of Srs2 ([@B21]). The srs2 variants were generated by site-directed mutagenesis (Stratagene) using the pET11c-(His)~9~-*SRS2* plasmid as template. The srs2 783--998 and srs2 783--1174 cloned in pGBKT7 were described elsewhere ([@B16]). The other two constructs, srs2 783--862 and srs2 783--914 in pGBKT7 were generated by site-directed mutagenic insertion of a stop codon in srs2 783--998/pGBKT7.

Protein purification
--------------------

The purification of the (His)~9~-tagged Srs2 and mutant srs2 proteins from *Escherichia coli* cells (50 g of cell paste, from 10 L of culture) was conducted as previously described ([@B15]), except that an affinity step on nickel NTA agarose was included to exploit the (His)~9~ tag. Peak fractions from the SP Sepharose column were combined and incubated with 2 ml of nickel-NTA agarose (Qiagen) for 2 h at 4°C with gentle mixing. The beads were washed with 50 ml of K buffer (20 mM K~2~HPO~4~, pH 7.4, 10% glycerol, 0.5 mM DTT and 0.5 mM EDTA) containing 300 mM KCl and 10 mM imidazole. Srs2 or mutant was eluted with 12 ml (8 fractions of 1.5 ml each) of 300 mM imidazole in K buffer containing 300 mM KCl. The peak fractions were diluted with 2.5 volumes of T buffer (20 mM Tris--HCl, pH 7.5, 10% glycerol, 0.5 mM DTT and 0.5 mM EDTA), before being fractionated in a 1 ml Mono S column, as described ([@B16]). The nearly homogeneous Srs2 and mutant protein preparations were concentrated to ∼5 mg/ml and stored in small aliquots at −80°C.

Rad51 and RPA were over-expressed in yeast and purified to near homogeneity, as described ([@B31]). Rad54 and PCNA were expressed in *E. coli* and purified to near homogeneity, as described ([@B32],[@B33]).

DNA substrates
--------------

The DNA helicase substrate was constructed using the unlabeled H3 oligonucleotide and ^32^P-labeled H1 oligonucleotide, as previously described ([@B15]). The ϕX174 (+) strand DNA was purchased from New England Biolabs. The D1 oligonucleotide used in the D-loop assay and the 150-mer E oligonucleotide used in electron microscopy have been described ([@B16],[@B34]).

Affinity pulldown assays
------------------------

Affi-gel 15 beads containing Rad51 (Affi-Rad51; 5 mg/ml) and bovine serum albumin (Affi-BSA; 12 mg/ml) were prepared as described previously ([@B35]). (His)~9~-tagged Srs2 or the indicated mutant variant (5 µg) was incubated with 5 µl of Affi-Rad51 or Affi-BSA in 30 µl of K buffer (20 mM K~2~HPO~4~, 10% glycerol, 0.5 mM EDTA, 0.01% Igepal and 1 mM DTT) containing 150 mM KCl for 1 hr on ice, with gentle mixing. The beads were washed twice with 150 µl of the same buffer before being treated with 30 µl of 2% SDS to elute the bound protein. The supernatant that contained unbound Srs2 or mutant, the second wash, and the SDS eluate, 10 µl of each, were analyzed by 7.5% SDS-PAGE and staining with Coomassie Blue. For the pull-down with srs2 Δ875--902 and Rad51, purified (His)~9~-tagged Srs2 or srs2 Δ875--902 (5 µg) was mixed with purified Rad51 (5 µg) in buffer K containing 150 mM KCl for 1 hr on ice, before adding 10 µl Ni-NTA agarose beads (Qiagen) and continuing the incubation for 30 min on ice with gentle mixing. The beads were washed twice with 150 µl of the same buffer before being treated with 30 µl of 2% SDS to elute the bound protein. The supernatant that contained unbound proteins, the second wash and the SDS eluate, 10 µl each, were analyzed by 7.5% SDS-PAGE and staining with Coomassie Blue. For examining Srs2-PCNA complex formation, nickel pull-downs were conducted as described above for srs2 Δ875--902 and Rad51, however purified PCNA (5 µg) was used in place of Rad51.

ATPase assay
------------

Purified Srs2 or truncated srs2 (35 nM) was incubated with 1 mM (γ-^32^P) ATP and ϕX174 (+) strand DNA (25 µM nucleotides) in 10 µl of buffer A (30 mM Tris--HCl, pH 7.5, 2.5 mM MgCl~2~, 1 mM DTT, 150 mM KCl and 100 µg/ml BSA) for 7.5 min at 37°C. The level of ATP hydrolysis was determined by thin layer chromatography with phosphorimaging analysis in a Personal Molecular Imager FX (Bio-Rad), as described ([@B35]).

DNA helicase assay
------------------

Purified Srs2 or mutant srs2 (40 nM) was incubated at 30°C for 5 min with the helicase substrate (300 nM nucleotides) in 10 µl of buffer H (30 mM Tris--HCl, pH 7.5, 2.5 mM MgCl~2~, 1 mM DTT, 100 mM KCl, 2 mM ATP and 100 µg/ml BSA). The reaction mixtures were stopped, deproteinized and resolved in a 10% non-denaturing polyacrylamide gel run in TAE buffer (40 mM Tris--HCl, pH 7.4, 0.5 mM EDTA) at 4°C. The gel was dried onto Whatman DE81 paper and subjected to phosphorimaging analysis.

D-loop reaction
---------------

Reactions were carried out in Buffer D (35 mM Tris--HCl, pH 7.5, 2 mM ATP, 2.5 mM MgCl~2~, 1 mM DTT, including an ATP-regenerating system consisting of 20 mM creatine phosphate and 20 µg/ml creatine kinase) and 50, 100 or 150 mM KCl in a final volume of 12.5 µl, as described previously ([@B16]). The ^32^P-labeled D1 oligonucleotide (3 µM nucleotides) was incubated with Rad51 (1 µM) for 5 min at 37°C to assemble the Rad51-ssDNA nucleoprotein filaments, followed by the incorporation of RPA (200 nM) and a 4 min incubation. Then, Rad54 (150 nM) was added, and following a 3 min incubation at 23°C, the reaction was initiated by adding pBluescript replicative form I DNA (50 µM base pairs), followed by a 6 min incubation at 30°C. The reaction was stopped by treatment with SDS (0.5%) and proteinase K (0.5 mg/ml) at 37°C for 5 min and resolved in a 1% agarose gel in TAE buffer. The gel was dried and subjected to phosphorimaging analysis. The percentage D-loop refers to the quantity of the D1 oligonucleotide substrate that has been converted into D-loop. When present, Srs2 or mutant srs2 (7.5 or 15 nM, as indicated) was added to the reaction with RPA.

DNA strand exchange reaction
----------------------------

Reactions were conducted at 37°C in Buffer R (35 mM Tris--HCl, pH 7.4, 2 mM ATP, 2.5 mM MgCl~2~, 50 mM KCl, 1 mM DTT and an ATP-regenerating system) in a final volume of 12.5 µl, as described previously ([@B36]). Rad51 (10 µM) was incubated with ϕX174 circular (+) strand (30 µM nucleotides) for 4 min, followed by a 6 min incubation with RPA (2 µM). The reaction was completed by adding spermidine hydrochloride (4 mM) and linear ϕX dsDNA (30 µM nucleotides). After an 80 min incubation, the reaction mixtures were deproteinized and resolved in 0.9% agarose gels, followed by ethidium bromide staining of the DNA species. When present, Srs2 or srs2 mutant (30--60 nM, as indicated) was added to the reaction with RPA.

Topoisomerase I-linked assay
----------------------------

Reactions were carried out in 10 µl of Buffer R at 37°C. Rad51 (4 µM) was incubated for 5 min with ϕX174 circular (+) strand DNA (20 µM nucleotides). Srs2 or mutant srs2 (60 or 80 nM, as indicated) and RPA (1 µM) were added, followed by a 4 min incubation. Topologically relaxed ϕX174 DNA (12.5 µM nucleotides) and 2.5 U calf thymus topoisomerase I (Invitrogen) were then incorporated to complete the reaction. After 8 min of incubation, the reaction mixtures were deproteinized and then subject to electrophoresis in 0.9% agarose gels. The DNA species were stained with ethidium bromide.

Electron microscopy
-------------------

Reaction mixtures were assembled as described for the DNA strand exchange reaction except that the 150-mer E oligonucleotide ([@B34]) (7.2 µM nucleotides), Rad51 (2.4 µM), RPA (0.5 µM), Srs2 or mutant srs2 (100 nM) were used. After a 3 min incubation, the reaction mixtures were diluted 10 times with buffer R lacking the ATP regenerating system, and a 3 µl aliquot was applied to 400-mesh grids coated with carbon film and which had been glow-discharged in air. The grids were stained with 2% uranyl acetate for 30 sec and rinsed with water before being examined with a Tecnai 12 Biotwin electron microscope (FEI company) equipped with a tungsten filament at 100 keV. Digital images were captured with a Morada (Olympus Soft Imaging Solutions) charge-coupled device camera at a nominal magnification of 87 000X.

Yeast strains
-------------

All yeast strains were in the W303 background (*leu2-3, 112 his3-11,15 ade2-1 ura3-1 trp1-1 can1-100 RAD5*). All constructs were verified by DNA sequencing. The strains were: HKY2070-4 (*srs2 1--860*), HKY2082-4 (*srs2 Δ875--902*), HKY590-1D (*srs2Δ*), HKY579-10A (*SRS2*), and F28-1A (*rad18Δ*).

Methyl methane sulfonate sensitivity
------------------------------------

Methyl methane sulfonate (MMS) sensitivity was determined using freshly made plates containing 0.005% MMS. Overnight cultures of strains were serially diluted and 4 µl aliquots of each dilution were applied onto YPD and YPD + MMS plates. Growth was assessed after 2 and 3 days at 30°C. The *rad18Δ* strain used has been described ([@B37]).

Determination of recombination rates
------------------------------------

Recombination rates were calculated by the median method of Lea and Coulson ([@B38]) using the *leu2-ecoRI::URA3::leu2-bstEII* recombination system as described previously ([@B39]). Three different strains derived from the same parental strains were analyzed for each genotype studied. For each strain, nine independent colonies were analyzed for each fluctuation test.

RESULTS
=======

Mapping the Srs2-Rad51 interaction in the yeast two-hybrid assay
----------------------------------------------------------------

In previously published work, we and others demonstrated an interaction between Rad51 and the carboxy-terminal region of Srs2 in the yeast two-hybrid assay, such that Srs2 fragments encompassing residues 783--1174 or residues 783--998 are capable of Rad51 association ([@B16],[@B40]) ([Figure 1](#F1){ref-type="fig"}A). Based on these two-hybrid data, additional constructs harboring two other portions of the Srs2 C-terminus were created and tested for Rad51 interaction. As shown in [Figure 1](#F1){ref-type="fig"}A, while the 783--914 fragment showed robust interaction with Rad51, no signal could be detected with the 783--862 fragment ([Figure 1](#F1){ref-type="fig"}A). Based on these results, we suspected the Rad51 interaction domain in Srs2 to lie between amino acid residues 862 and 914.

C-terminally truncated variants of Srs2 deficient for Rad51 interaction
-----------------------------------------------------------------------

To verify the yeast two-hybrid data *in vitro* and for additional biochemical analyses, we constructed various C-terminally truncated Srs2 variants---1--998, 1--910, 1--890, 1--875 and 1--860---by introducing stop codons within the pET11c-(His)~9~-*SRS2*plasmid. The tagged full length Srs2 and the truncated variants were expressed in *E. coli*by the use of the IPTG-inducible T7 promoter. The chromatographic procedure for purification of the (His)~9~-tagged proteins was modified from the original protocol ([@B16]) to include a nickel affinity step. By this method, we were able to purify full length Srs2 and the truncated srs2 variants to near homogeneity ([Figure 1](#F1){ref-type="fig"}C).

To test for interaction with Rad51, purified Srs2 and the five srs2 truncation mutant proteins were each mixed with Affi-gel beads that contained covalently conjugated Rad51 protein (Affi-Rad51) or bovine serum albumin (Affi-BSA). The beads were washed with buffer before being treated with SDS to elute the bound Srs2 or srs2 mutant protein, followed by SDS-PAGE analysis. Consistent with results from the yeast two-hybrid analysis, full length Srs2, srs2 1--998, and srs2 1--910 were retained on the Affi-Rad51 beads but not on the Affi-BSA beads ([Figure 2](#F2){ref-type="fig"}A and B). Importantly, and consistent with the yeast two-hybrid results, srs2 1--860 did not bind the Affi-Rad51 beads ([Figure 2](#F2){ref-type="fig"}A), indicating that it is defective for Rad51 interaction. Moreover, while srs2 1--890 showed only a slightly attenuated affinity for Affi-Rad51, little or no srs2 1--875 was retained on the Affi-Rad51 beads ([Figure 2](#F2){ref-type="fig"}A). These results indicated that the region between amino acid residues 875 and 910 in Srs2 is likely critical for Rad51 interaction. Figure 2.Mapping of Rad51 interaction by *in vitro* pull-down assay. Purified Srs2, srs2 1--998, srs2 1--910, srs2 1--890, srs2 1--875 and srs2 1--860 were mixed with Affi-Rad51 beads (**A**) or Affi-BSA beads (**B**) The supernatant that contained unbound protein (S), wash (W) and the SDS eluate (E) were resolved by SDS-PAGE and stained with Coomassie Blue. (**C**) In panel I, Purified srs2 Δ875--902, 1 µg, analyzed by SDS-PAGE and stained with Coomassie Blue. In panel II, Srs2 and srs2 Δ875--902 were combined with purified Rad51 and mixed with nickel NTA agarose beads. The supernatant that contained unbound protein (S), wash (W) and the SDS eluate (E) were resolved by SDS-PAGE and stained with Coomassie Blue (lanes 1--6). As control, Rad51 alone was incubated with nickel NTA agarose beads (lanes 7--9). In panel III, Srs2 and srs2 Δ875--902 were examined for PCNA interaction (lanes 1--9) following the same procedure in panel II.

Based on the above domain mapping results, we created a form of Srs2 that lacks amino acid residues 875--902, but is otherwise full length. The srs2 Δ875*--*902 mutant was expressed and purified to near homogeneity following the strategy used for other Srs2 forms ([Figure 2](#F2){ref-type="fig"}C, panel I) and examined for interaction with Rad51. The internal deletion mutant exhibited some non-specific binding to Affi-BSA beads, thus the pulldown analysis was conducted using nickel NTA affinity beads to isolate the protein complex via the (His)~9~-tag on Srs2. Full-length Srs2 was able to bind Rad51 as expected, but little or no Rad51 associated with srs2 Δ875*--*902 ([Figure 2](#F2){ref-type="fig"}C, panel II). This provides evidence that the region between residues 875*--*902 of Srs2 is needed for Rad51 interaction. Additionally, we tested the ability of the internal deletion mutant to bind PCNA. The PCNA interaction domain is known to lie in the far C-terminus of Srs2 ([@B20],[@B41]), and consistent with this, we found that srs2 Δ875*--*902 is just as adept as Srs2 in PCNA interaction ([Figure 2](#F2){ref-type="fig"}C, panel III).

C-terminal truncations do not affect ATPase and helicase activities
-------------------------------------------------------------------

The deduced Rad51 interaction domain in Srs2 resides distally to the catalytic domains that are concerned with ATP hydrolysis and helicase activity ([Figure 1](#F1){ref-type="fig"}B), so we expected even the shortest of our srs2 truncation variants, i.e. srs2 1*--*860, to retain the ability to hydrolyze ATP and unwind DNA. To verify this expectation, the purified srs2 mutant proteins were first tested for their ability to hydrolyze ATP. We showed previously that ATP hydrolysis by Srs2 is ssDNA-dependent ([@B15]), and, as summarized in [Figure 3](#F3){ref-type="fig"}A, all of the srs2 truncation variants show a level of ssDNA-dependent ATPase activity comparable to that of the wild-type protein. We next examined the various srs2 truncation mutant proteins for DNA helicase activity using a ^32^P-labeled substrate that contained a 40 bp duplex region with a 40-nucleotide 3′-ssDNA overhang \[[Figure 3](#F3){ref-type="fig"}B and ([@B15])\]. As shown in [Figure 3](#F3){ref-type="fig"}B, the srs2 mutants were as adept as the full length Srs2 protein in unwinding the DNA substrate. Based on the above results, we can conclude that all of the truncated forms of srs2 that we have generated possess ATP hydrolysis and DNA helicase activities comparable to those of the wild-type counterpart. Figure 3.Proficiency of the srs2 mutants in ATP hydrolysis and DNA unwinding. (**A**) Graphical representation of the ssDNA-dependent ATPase activity of Srs2 and srs2 mutants. (**B**) The DNA helicase activity of Srs2 and srs2 mutants was assayed using a 3′-tailed duplex substrate (panel I) and the results quantified (panel II)*.* NP, no protein control; HD, heat-denatured substrate. In all cases, error bars represent the standard deviations derived from three independent experiments.

Interaction of Srs2 with Rad51 is critical for its anti-recombinase function
----------------------------------------------------------------------------

We ([@B16]) and others ([@B17]) demonstrated previously that Srs2 inhibits the recombinase activity of Rad51 ([@B42]). We used the D-loop assay to test the anti-recombinase activity of our srs2 truncation mutants ([Figure 4](#F4){ref-type="fig"}A). As we reported previously, the addition of a small amount of Srs2 (7.5*--*15 nM) to the D-loop reaction containing Rad51, Rad54 and the heterotrimeric ssDNA-binding factor RPA led to pronounced inhibition of the reaction ([Figure 4](#F4){ref-type="fig"}B). The two srs2 truncation mutants, srs2 1*--*998 and srs2 1*--*910, that are able to interact with Rad51 also inhibited the D-loop reaction to a comparable degree as Srs2 ([Figure 4](#F4){ref-type="fig"}B). However, the srs2 1*--*875 and srs2 1*--*860 mutants, which are deficient in Rad51 interaction, exerted only a slight inhibitory effect on the D-loop reaction ([Figure 4](#F4){ref-type="fig"}B). The slight inhibition observed with increasing amounts of srs2 1*--*875 or srs2 1*--*860 could be due to a residual interaction with Rad51. Likewise, the srs2 Δ875*--*902 mutant that is also deficient in Rad51 interaction is again significantly impaired for the ability to suppress the D-loop reaction ([Figure 4](#F4){ref-type="fig"}C). Interestingly, the srs2 1*--*890 truncation mutation that is partially attenuated for Rad51 interaction showed an intermediate level of inhibition of the D-loop reaction, with the defect being much more obvious at higher concentrations of KCl ([Figure 4](#F4){ref-type="fig"}B, panel III), which very likely weakened the residual interaction between Rad51 and this srs2 mutant. Altogether, these results revealed interaction with Rad51 as important for the anti-recombinase activity of Srs2. Figure 4.Relevance of the Srs2-Rad51 complex in the attenuation of the D-loop reaction. (**A**) D-loop reaction scheme. (**B**) In panel I, the radiolabeled D1 oligonucleotide was incubated with Rad51, Rad54, RPA (lanes 2--12) and with or without Srs2, srs2 1--998, srs2 1--910, srs2 1--875 or srs2 1--860 (7.5 or 15 nM) and then pBluescript form I DNA was incorporated. The reaction (lane 2) without Srs2 or mutant srs2 is designated as standard (Std) and corresponded to conversion of 43% of the input D1 oligonucleotide into the D-loop product. Lane 1 contained the DNA substrates but no protein. The KCl concentration was 50 mM KCl in these reactions and the results were quantified and plotted in panel II. In panel III, the results from D-loop reactions carried out at 50, 100, and 150 mM KCl with 15 nM of Srs2 or srs2 mutant were quantified and plotted. The D-loop product in the standard (Std) was 58%, 61% and 66% at 50, 100 and 150 mM KCl, respectively. (**C**) Panel I shows D-loop reactions with 7.5 and 15 nM Srs2, srs2 Δ875--902 or srs2 1--860 at 50 mM KCl. The D-loop in the standard (Std) was 54%. The results were quantified and plotted in panel II. In all cases, error bars represent the standard deviations derived from three independent experiments.

Examination of Rad51-interaction defective srs2 mutants in the DNA strand exchange reaction
-------------------------------------------------------------------------------------------

We applied a DNA strand exchange system that uses plasmid length DNA substrates to seek independent verification that interaction with Rad51 is critical for the anti-recombinase attribute of Srs2. In this system, Rad51-made DNA joint molecules are processed by DNA strand exchange to yield nicked circular duplex as the final reaction product ([@B16],[@B18]) ([Figure 5](#F5){ref-type="fig"}A). As expected ([@B16]), the addition of a catalytic quantity of Srs2 (30 and 60 nM) strongly suppressed the DNA strand exchange reaction ([Figure 5](#F5){ref-type="fig"}B). In contrast, little or no attenuation of DNA strand exchange efficiency was seen when srs2 1*--*860 or srs2 Δ875*--*902 was tested ([Figure 5](#F5){ref-type="fig"}B). The above results support our conclusion that the efficacy of Srs2's anti-recombinase activity is contingent upon Rad51 interaction. Figure 5.Anti-recombinase activity examined by DNA strand exchange. (**A**) The DNA strand exchange scheme. (**B**) In panel I, circular ϕX174 (+) strand DNA was incubated with Rad51, RPA, and in the absence or presence of Srs2, srs2 Δ875--902 or srs2 1--860 (30 and 60 nM), and then spermidine and linear ϕX dsDNA were added and the reaction incubated for either 40 or 80 min. A reaction without Srs2 or mutant srs2, designated as standard (Std; lane 2) served as a control. The DNA substrates were also incubated without any protein (Bl; lane 1). Only the results from the 80 min time-point are shown. In panel II, the sum of joint molecules and nicked circular duplex from the 40 min and 80 min time-points of reactions that contained 30 nM Srs2 or srs2 mutant was plotted. In all cases, error bars represent the standard deviations derived from the results of three independent experiments.

Relevance of protein--protein interaction in Rad51 presynaptic filament disruption
----------------------------------------------------------------------------------

The above results obtained using C-terminally truncated srs2 mutant proteins helped establish that interaction with Rad51 is critical for Srs2's ability to attenuate Rad51-mediated HR homologous DNA pairing and strand exchange. We employed a biochemical assay to provide evidence that the impairment of anti-recombinase activity in the truncated srs2 mutants stems from an inability to disrupt the Rad51 presynaptic filament. In this biochemical test, pre-assembled presynaptic filaments are incubated with Srs2 or one of the srs2 mutants together with RPA, and then topologically relaxed duplex DNA is added to trap the Rad51 molecules freed from ssDNA as a result of anti-recombinase function. Since Rad51 binding induces lengthening of the DNA trap, the level of anti-recombination function can be conveniently monitored as a DNA linking number change upon treatment of the duplex with topoisomerase I \[[Figure 6](#F6){ref-type="fig"}A, ([@B16])\]. The product of this reaction, an underwound DNA species called form U ([Figure 6](#F6){ref-type="fig"}B, lane 2), is resolved from other DNA species by agarose gel electrophoresis and then revealed by ethidium bromide staining. Figure 6.Rad51 presynaptic filament disruption as measured by a topoisomerase-linked assay. (**A**) Reaction scheme for detecting Rad51 presynaptic filament disruption. (**B**) Rad51 presynaptic filaments were incubated without or with Srs2, srs2 1--910, srs2 Δ875--902, srs2 1--875 or srs2 1--860 (60 and 80 nM) before the addition of relaxed DNA and topoisomerase I (lanes 3--13). Lane 2 contains Form U DNA made by incubating topologically relaxed DNA with Rad51 and topoisomerase I. Lane 1 contains topologically relaxed DNA.

As expected, the addition of Srs2 to the presynaptic filaments led to the generation of form U, indicative of the release of Rad51 from the ssDNA \[[Figure 6](#F6){ref-type="fig"}B, ([@B15])\]. Abundant Form U DNA was also seen when the Rad51 interaction proficient srs2 1*--*910 mutant, which we showed earlier to possess the wild-type level of anti-recombinase activity (e.g. [Figure 4](#F4){ref-type="fig"}B), was incubated with the presynaptic filaments ([Figure 6](#F6){ref-type="fig"}B). Importantly, the Rad51-interaction deficient srs2 1*--*860, srs2 1*--*875 and srs2 Δ875*--*902 mutants, which we found to be impaired for anti-recombinase activity, were incapable of producing a significant amount of Form U DNA ([Figure 6](#F6){ref-type="fig"}B). These results thus provide direct evidence that dissociation of the Rad51 presynaptic filament by Srs2 is reliant upon the interaction between Srs2 and Rad51.

Analysis by electron microscopy
-------------------------------

We also employed electron microscopy to examine and quantify the disruption of Rad51 presynaptic filaments by Srs2 and several of the srs2 truncation mutants. For this purpose, we assembled Rad51 presynaptic filaments on a 150-mer oligonucleotide ([@B43]) and then incubated these filaments with Srs2 or one of several srs2 mutants in conjunction with RPA. The reaction mixtures were diluted with buffer, applied onto carbon grids, and then examined by electron microscopy to quantify the levels of Rad51 presynaptic filament and RPA--ssDNA complex in each case. As summarized in [Figure 7](#F7){ref-type="fig"}, Rad51 presynaptic filaments accounted for ∼80% of the nucleoprotein complexes in Srs2's absence, whereas these filaments represented only a little over 20% of the nucleoprotein complexes upon the addition of Srs2. As we had anticipated, srs2 1--910 was just as adept as the full-length protein in Rad51 presynaptic filament dissociation, but, importantly, srs2 1--875 or srs2 Δ875--902 was much less effective in this regard ([Figure 7](#F7){ref-type="fig"}). Overall, the results from the EM analysis provided independent support for Rad51 interaction as a key determinant in the efficacy of Srs2 as an anti-recombinase. Figure 7.Quantification of Rad51 presynaptic filament disruption by electron microscopy. (**A**) Representative Rad51 nucleoprotein filaments (I) or RPA-ssDNA complexes (II) assembled on 150-mer ssDNA. The scale bar represents 50 nm. (**B**) Distribution of Rad51 presynaptic filaments and RPA-ssDNA complexes observed following incubation without or with 100 nM Srs2, srs2 1--910, srs2 Δ875--902 or srs2 1--875.

Phenotypic analysis of *srs2* mutants
-------------------------------------

We wished to examine the genetic behavior of some of our srs2 mutants. Yeast strains were created which lacked Srs2 (*srs2Δ),* or that lacked amino acid residues 861--1174 (the *1--860* allele) or 875--902 (the *Δ875--902*allele) of Srs2. As expected ([@B8]), the deletion of *SRS2* suppressed the DNA damage sensitivity of the *rad18Δ* mutation ([Figure 8](#F8){ref-type="fig"}A). DNA damage sensitivity of *rad18Δ* mutants can be suppressed by nonfunctional *srs2* mutations in a *RAD51-*dependent manner ([@B13]). Suppression of the *rad18Δ* MMS sensitivity was seen with the *srs2 1--860*but not the *srs2 Δ875--902*allele ([Figure 8](#F8){ref-type="fig"}A). Figure 8.Phenotypic analysis of srs2 1-860 and srs2 Δ875-902. (**A**) The ability of the *srs2 1--860*and *srs2 Δ875--902* alleles to suppress the MMS sensitivity of *rad18Δ*cells was examined. Platings on both YPD and YPD containing 0.005% MMS are shown. (**B**) Rates of recombination between the *leu2-RI* and *leu2-bsteII* alleles were determined and the results graphed. The rates shown represent the mean from three independent fluctuation tests performed for each strain. Error bars are the standard deviations derived from this mean of three independent rate determinations. Asterisks denote significant results, as determined by *t*-tests: \*\**P* \< 0.005; \**P* \< 0.05. Specifically, the rates for *SRS2* and *srs2Δ875--902* are significantly different (*P* = 0.00004), the rates for *SRS2*and *srs2 Δ875--902* are marginally different (*P* = 0.0117), and the rates for *SRS2* and *srs2 1--860* are significantly different (*P* = 0.0016).

We next examined the *srs2* mutant strains for a hyper-recombination phenotype. Consistent with published results ([@B10]), we observed a 4-fold increase in the rate of gene conversion events in *srs2Δ* cells ([Figure 8](#F8){ref-type="fig"}B). A similarly elevated gene conversion rate, one that was three-fold that of wild-type ([Figure 8](#F8){ref-type="fig"}B), was found for the *srs2 1--860*mutant. In contrast, the *srs2 Δ875--902* gave a gene conversion rate that is only slightly higher than the wild-type control ([Figure 8](#F8){ref-type="fig"}B). These findings fit with our observations that the srs2 1--860 mutant protein is quite defective in Rad51 interaction and in the inhibition of Rad51-mediated reactions, while the srs2 Δ875--902 mutant protein retains some ability to interact with Rad51 and possesses residual anti-recombinase activity.

DISCUSSION
==========

Despite the important contributions that HR makes to the elimination of deleterious DNA lesions and the re-establishment of injured DNA replication forks, it must be tightly regulated so as to prevent untimely events that interfere with other DNA and replication fork repair processes, or to avoid the generation of toxic nucleoprotein intermediates that trigger prolonged cell cycle arrest ([@B6],[@B7],[@B11],[@B44]). Moreover, crossover HR events are disfavored in mitotic cells, as they can give rise to undesirable chromosome rearrangements, such as translocations. Genetic and other companion analyses have found several pathways able to attenuate undesirable HR events or promote the usage of the conservative SDSA pathway that does not entail the generation of crossovers. Importantly, all of these HR regulatory pathways are dependent on a DNA helicase. Specifically, the human BLM helicase, and likely its *S. cerevisiae*counterpart Sgs1, functions with Topo IIIα (Top 3 in yeast), a type 1A topoisomerase, and other associated factors to resolve key HR DNA intermediates, such as the double Holliday structure, to non-crossover recombinants in a process termed double Holliday junction dissolution ([@B45]). Interestingly, the Srs2 helicase suppresses spurious HR events and also prevents crossover formation via a unique ability to disrupt the Rad51 presynaptic filament ([@B16],[@B17]). Genetic and biochemical evidence has been presented to implicate the mammalian RECQ5 helicase in HR regulation via the same general mechanism as Srs2 ([@B43]). More recently, a separate means of HR regulation has been documented for the *S. cerevisiae* Mph1 helicase and its orthologues human FANCM and *Schizosaccharomyces pombe* Fml1; these orthologous helicases have been suggested to promote the use of the SDSA pathway of HR by disrupting the D-loop intermediate made by the Rad51 recombinase protein ([@B34],[@B46]). Finally, the human RTEL1 helicase has also been shown to disrupt Rad51-made D-loops, but this novel attribute of RETL1 is thought to exert a general suppressive effect on HR frequency rather than fulfilling a regulatory role. Importantly, mutations in all the above helicases compromise genome instability and in some cases are associated with the tumor phenotype ([@B43],[@B47],[@B48]).

Several of the aforementioned helicases, including Srs2, RECQ5 and BLM/Sgs1 are known to physically interact with Rad51 ([@B16],[@B43],[@B49]), although the functional significance of these protein-protein interactions has not been addressed. In this study, we have strived to address the functional relevance of the Srs2-Rad51 complex at the biochemical level. Specifically, by a combination of yeast two-hybrid analysis and biochemical mapping, we have narrowed the Rad51 interaction domain to a short region within the Srs2 C-terminus, and have taken advantage of this information to generate several truncation mutants of Srs2 that retain wild-type levels of ATPase and helicase activities but are specifically compromised for Rad51 interaction. Importantly, with both biochemical means and electron microscopy, we have demonstrated a diminished ability of these srs2 mutants to attenuate Rad51-mediated HR reactions and to dismantle the Rad51 presynaptic filament, in concordance with the degree of Rad51 interaction deficiency. We note that, by employing a kinetic assay involving the use of a fluorescently labeled DNA substrate, Antony *et al.* ([@B50]) also showed recently that the srs2 1--860 mutant is deficient in anti-recombinase activity. Thus, in aggregate, our findings and those of Antony *et al.* ([@B50]) reveal that the efficacy of Srs2 as an anti-recombinase is dependent on its physical interaction with Rad51. Consistent with our biochemical results, we found that the *srs2 1--860* mutant displays a hyper-recombination phenotype. Since the srs2 1--860 mutant protein retains wild-type levels of ATPase and helicase activities, our results thus provide evidence that the Srs2 helicase domain alone is insufficient for anti-recombinase function in cells. We have shown that the srs2 Δ875--902 mutant protein is less impaired for Rad51 interaction or for the ability to inhibit Rad51-mediated reactions *in vitro*. The phenotype of *srs2 Δ875--902* cells is accordingly mild or near wild-type.

Like Srs2, the human RECQ5 helicase associated with Rad51 physically, inhibits the Rad51-mediated D-loop reaction, and catalyzes the removal of Rad51 from ssDNA in a manner that is dependent on its ATPase activity ([@B43]). Based on these functional similarities between Srs2 and RECQ5, it seems reasonable to suggest that Rad51 interaction is also a determinant of the anti-recombinase activity of RECQ5. The results of Antony *et al.* have suggested that Srs2 enhances ATP hydrolysis by Rad51 within the presynaptic filament, thereby hastening Rad51 dissociation from DNA ([@B50]). It will be interesting to test whether RECQ5 also acts by a similar mechanism.

We note that Srs2 becomes phosphorylated on multiple sites in response to intra-S phase DNA damage ([@B26]), and several of these phosphorylation sites are located within the C-terminus of the protein, including two such sites in the region spanning residues 875--902 ([@B51]) that we know are important for complex formation with Rad51 (this work). It will be particularly interesting to ascertain how C-terminal phosphorylation of Srs2 in response to DNA damage regulates its anti-recombinase function via an influence on complex formation with Rad51.
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